Stocks
Regeneron Pharmaceuticals, Inc.REGN
NASDAQHealthcareBiotechnology$745.77-0.11%
A leading biotechnology firm specializing in the discovery and commercialization of medicines for serious diseases, Regeneron is particularly known for its work in ophthalmology, oncology, and immunology. Investors closely monitor its pipeline of innovative therapies and its strong revenue growth driven by flagship products like Eylea and Dupixent.
Market Cap: $77.5B52W Range: $476.49 – $821.11
Congressional Interest in Regeneron Pharmaceuticals, Inc. (REGN)
6 members of Congress have disclosed 32 trades in Regeneron Pharmaceuticals, Inc. (REGN), a Healthcare company. The buy/sell breakdown shows 15 purchases versus 17 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
32
Unique Politicians
6
Buys
15
Sells
17
Who in Congress Is Trading REGN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-03-08 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2016-02-26 | K. Michael Conaway | sell | $1K – $15K |